Medicare Enrolled
Mark Weir, MB CHB
Pulmonary Disease · Marlton, NJ
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Weir from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Weir?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Weir
Mark Weir is a pulmonary disease specialist in Marlton, NJ, with 13 years of NPI registration. Based on federal Medicare data, Weir performed 1,394 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Weir received a total of $6,814 from 23 pharmaceutical and/or device companies across 86 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Weir is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years of NPI registration
▲ 1,394 Medicare services
$6,814 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗1,394
Medicare services
Bottom 48% in NJ for pulmonary disease
Not available
Unique patients (not deduplicated)
$102
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
503 | $64 | $162 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
170 | $98 | $243 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
156 | $180 | $596 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
153 | $143 | $430 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
123 | $110 | $284 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
43 | $138 | $365 |
| Bronchial irrigation and suction for cell collection This procedure uses an endoscope to flush and suction the lung airways in order to collect cells for testing. |
33 | $53 | $436 |
| Bronchoscopy with ultrasound and lymph node sampling A procedure using an endoscope and ultrasound to examine the lung airways and collect samples from 1 to 2 lymph nodes. |
28 | $184 | $720 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
27 | $51 | $185 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
22 | $110 | $291 |
| New patient office visit, complex (60-74 min) | 19 | $166 | $483 |
| Computer-assisted navigation of lung airways This procedure uses computer technology to guide an endoscope through the airways of the lungs for precise navigation. |
17 | $80 | $315 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
17 | $74 | $200 |
| Chest fluid aspiration with imaging guidance This procedure involves removing fluid from the chest cavity using imaging technology to guide the needle placement. |
16 | $92 | $363 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
16 | $24 | $120 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
14 | $49 | $180 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
13 | $39 | $145 |
| Bronchoscopy with ultrasound and lymph node sampling A procedure using a scope and ultrasound to examine the airways and collect tissue samples from three or more lymph nodes. |
12 | $204 | $798 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
12 | $154 | $395 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$6,814
Total received (2018-2024)
Avg $973/year across 7 years
Top 20% in NJ for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
23
Companies
86
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$837
2023
$1,203
2022
$4,230
2021
$56
2020
$13
2019
$12
2018
$464
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$330
GlaxoSmithKline, LLC.
$221
Regeneron Healthcare Solutions, Inc.
$64
GENZYME CORPORATION
$47
Actelion Pharmaceuticals US, Inc.
$31
HARMONY BIOSCIENCES LLC
$29
Philips North America LLC
$22
PFIZER INC.
$18
Avadel CNS Pharmaceuticals, LLC
$16
Takeda Pharmaceuticals U.S.A., Inc.
$16
Boehringer Ingelheim Pharmaceuticals, Inc.
$15
Mylan Specialty L.P.
$14
Merck Sharp & Dohme LLC
$13
Top 3 companies account for 73.5% of 2024 payments
All-time payments by company (2018-2024) ›
Intuitive Surgical, Inc.
$4,801
EMD Serono, Inc.
$420
AstraZeneca Pharmaceuticals LP
$398
GlaxoSmithKline, LLC.
$346
Vifor Pharma, Inc.
$160
Regeneron Healthcare Solutions, Inc.
$116
Actelion Pharmaceuticals US, Inc.
$72
GENZYME CORPORATION
$61
Boehringer Ingelheim Pharmaceuticals, Inc.
$60
Philips Electronics North America Corporation
$52
Takeda Pharmaceuticals U.S.A., Inc.
$49
Circassia Pharmaceuticals Inc
$44
Harmony Biosciences LLC
$44
HARMONY BIOSCIENCES LLC
$29
Merck Sharp & Dohme LLC
$26
Amgen Inc.
$25
Philips North America LLC
$22
PFIZER INC.
$18
Avadel CNS Pharmaceuticals, LLC
$16
Ambu Inc.
$14
Mylan Specialty L.P.
$14
Covidien LP
$13
Electromed, Inc.
$12
Top 3 companies account for 82.5% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · AIRSUPRA · ARALAST · AREXVY · BREZTRI · DUPIXENT · Da Vinci Surgical System · FASENRA · ION · LUMRYZ · NUCALA · OFEV · OPSUMIT · PREVNAR 20 · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · UPTRAVI · Veltassa · WAKIX · WINREVAIR · YUPELRI · superDimension
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Pulmonary diseases in nearby ZIP areas
241
County median income
$105,271
Nearest hospital to ZIP centroid (approximate)
WEISMAN CHILDRENS REHABILITATION HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Weir is a clinical cardiology specialist, with moderate Medicare volume.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Weir experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Weir performed 503 hospital follow-up visit, moderate complexity services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Weir receive payments from pharmaceutical companies?
Yes. Weir received a total of $6,814 from 23 companies across 86 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Weir's costs compare to other pulmonary diseases in Marlton?
Weir's average Medicare payment per service is $102. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Weir) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Marlton
Browse pulmonary diseases in Marlton ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NJ
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NJ
Which NJ pulmonary diseases receive the most from drug and device companies.
By company
Intuitive Surgical, Inc. Payments to Doctors
See all physicians who received payments from Intuitive Surgical, Inc.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology